Evogliptin/metformin - Dong-A ST

Drug Profile

Evogliptin/metformin - Dong-A ST

Alternative Names: DA-1229_01; Sugamet

Latest Information Update: 29 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A ST
  • Class Amides; Antihyperglycaemics; Biguanides; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 05 Jan 2016 Registered for Type-2 diabetes mellitus in South Korea (PO)
  • 01 Jun 2015 Preregistration for Type-2 diabetes mellitus in South Korea (PO)
  • 27 Nov 2014 Dong-A ST completes a phase I trial in Healthy volunteers in South Korea (NCT02167061)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top